Global cancer statistics, CA: A Cancer Journal for Clinicians, vol.82, issue.19 suppl, pp.69-90, 2011. ,
DOI : 10.3322/caac.20107
Inflammation and cancer, Nature, vol.2, issue.6917, pp.860-867, 2002. ,
DOI : 10.1006/cyto.1996.0074
Epidemiologic association between prostatitis and prostate cancer, Urology, vol.60, issue.1, pp.78-83, 2002. ,
DOI : 10.1016/S0090-4295(02)01637-0
Chronic inflammation is negatively associated with prostate cancer and high-grade prostatic intraepithelial neoplasia on needle biopsy, International Journal of Clinical Practice, vol.52, issue.3, pp.425-455, 2007. ,
DOI : 10.1111/j.1742-1241.2006.00905.x
Distribution of Inflammation, Pre-Malignant Lesions, Incidental Carcinoma in Histologically Confirmed Benign Prostatic Hyperplasia: A Retrospective Analysis, European Urology, vol.43, issue.2, pp.164-75, 2003. ,
DOI : 10.1016/S0302-2838(02)00548-1
The Controversial Relationship Between Benign Prostatic Hyperplasia and Prostate Cancer: The Role of Inflammation, European Urology, vol.60, issue.1, pp.106-123, 2011. ,
DOI : 10.1016/j.eururo.2011.03.055
Combination Therapy With Rofecoxib and Finasteride in the Treatment of Men With Lower Urinary Tract Symptoms (LUTS) and Benign Prostatic Hyperplasia (BPH), The Journal of Urology, vol.175, issue.2, pp.72-80, 2005. ,
DOI : 10.1016/S0022-5347(05)00367-8
TLR2 and TLR4 serve distinct roles in the host immune response against Mycobacterium bovis BCG, Journal of Leukocyte Biology, vol.74, issue.2, pp.277-86, 2003. ,
DOI : 10.1189/jlb.0103026
BCG immunotherapy of bladder cancer: 20 years on, The Lancet, vol.353, issue.9165, pp.1689-94, 1999. ,
DOI : 10.1016/S0140-6736(98)07422-4
Identification of hTLR10: a novel human Toll-like receptor preferentially expressed in immune cells, Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression, vol.1518, issue.1-2, pp.157-61, 2001. ,
DOI : 10.1016/S0167-4781(00)00289-X
A cell biological view of Toll-like receptor function: regulation through compartmentalization, Nature Reviews Immunology, vol.321, issue.8, pp.535-577, 2009. ,
DOI : 10.1038/nri2587
The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors, Nature Immunology, vol.1799, issue.5, pp.373-84, 2010. ,
DOI : 10.1126/science.1179050
Toll-like receptor control of the adaptive immune responses, Nature Immunology, vol.169, issue.10 ,
DOI : 10.1126/science.1076071
Pathogen Recognition and Innate Immunity, Cell, vol.124, issue.4, pp.783-801, 2006. ,
DOI : 10.1016/j.cell.2006.02.015
Toll-like Receptors and Their Crosstalk with Other Innate Receptors in Infection and Immunity, Immunity, vol.34, issue.5, pp.637-50, 2011. ,
DOI : 10.1016/j.immuni.2011.05.006
Toll-like receptors in the pathogenesis of human disease, Nature Immunology, vol.171, issue.10, pp.975-984, 2004. ,
DOI : 10.1016/S1074-7613(03)00323-6
Cutting Edge: Naturally Occurring Soluble Form of Mouse Toll-Like Receptor 4 Inhibits Lipopolysaccharide Signaling, The Journal of Immunology, vol.165, issue.12, pp.6682-6688, 2000. ,
DOI : 10.4049/jimmunol.165.12.6682
The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses, Nature Immunology, vol.164, issue.10, pp.1052-60, 2004. ,
DOI : 10.1074/jbc.M103378200
Negative regulation of Toll-like receptor-mediated immune responses, Nature Reviews Immunology, vol.168, issue.6, pp.446-58, 2005. ,
DOI : 10.1038/ni1198
Suppression of LPS-induced TNF-alpha production in macrophages by cAMP is mediated by PKA-AKAP95-p105, Sci Signal, vol.2, p.28, 2009. ,
The Adenosine System Selectively Inhibits TLR-Mediated TNF-?? Production in the Human Newborn, The Journal of Immunology, vol.177, issue.3, pp.1956-66, 2006. ,
DOI : 10.4049/jimmunol.177.3.1956
Infection, Journal of Biological Chemistry, vol.282, issue.39, pp.28929-28967, 2007. ,
DOI : 10.1074/jbc.M702633200
URL : https://hal.archives-ouvertes.fr/pasteur-01179295
A trio of microRNAs that control Toll-like receptor signalling, International Immunology, vol.23, issue.7, pp.421-426, 2011. ,
DOI : 10.1093/intimm/dxr034
MicroRNAs: the fine-tuners of Toll-like receptor signalling, Nature Reviews Immunology, vol.183, issue.3, pp.163-75, 2011. ,
DOI : 10.1038/nri2957
MicroRNA-7- regulated TLR9 signaling-enhanced growth and metastatic potential of human lung cancer cells by altering the phosphoinositide-3- kinase ,
MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response, Proceedings of the National Academy of Sciences, vol.109, issue.31, pp.2110-2116, 2012. ,
DOI : 10.1073/pnas.1209414109
HMGB1 and RAGE in Inflammation and Cancer, Annual Review of Immunology, vol.28, issue.1, pp.367-88, 2010. ,
DOI : 10.1146/annurev.immunol.021908.132603
Natural adjuvants: Endogenous activators of dendritic cells, Nature Medicine, vol.81, issue.11, pp.1249-55, 1999. ,
DOI : 10.1146/annurev.immunol.2.1.461
Toll-like receptor 4???dependent contribution of the immune system to anticancer chemotherapy and radiotherapy, Nature Medicine, vol.289, issue.9, pp.1050-1059, 2007. ,
DOI : 10.1038/nm1622
URL : https://hal.archives-ouvertes.fr/hal-00316924
Decoding Cell Death Signals in Inflammation and Immunity, Cell, vol.140, issue.6, pp.798-804, 2010. ,
DOI : 10.1016/j.cell.2010.02.015
Calreticulin, a Peptide-binding Chaperone of the Endoplasmic Reticulum, Elicits Tumor- and Peptide-specific Immunity, The Journal of Experimental Medicine, vol.3, issue.5, pp.797-802, 1999. ,
DOI : 10.1016/S0960-9822(98)70278-7
Human Tumor Cells Killed by Anthracyclines Induce a Tumor-Specific Immune Response, Cancer Research, vol.71, issue.14, pp.4821-4854, 2011. ,
DOI : 10.1158/0008-5472.CAN-11-0950
Molecular Interactions between Dying Tumor Cells and the Innate Immune System Determine the Efficacy of Conventional Anticancer Therapies, Cancer Research, vol.68, issue.11, pp.4026-4056, 2008. ,
DOI : 10.1158/0008-5472.CAN-08-0427
The innate and early immune response to pathogen challenge in the female genital tract and the pivotal role of epithelial cells, Journal of Reproductive Immunology, vol.57, issue.1-2, pp.61-79, 2002. ,
DOI : 10.1016/S0165-0378(02)00019-0
Inflammation and prostate cancer: A focus on infections, Current Urology Reports, vol.2, issue.3, pp.243-252, 2008. ,
DOI : 10.1007/s11934-008-0042-z
Susceptibility of Prostate Epithelial Cells to Chlamydia muridarum Infection and Their Role in Innate Immunity by Recruitment of Intracellular Toll-Like Receptors 4 and 2 and MyD88 to the Inclusion, Infection and Immunity, vol.74, issue.12, pp.6973-81, 2006. ,
DOI : 10.1128/IAI.00593-06
Prostate epithelial cells can act as early sensors of infection by up-regulating TLR4 expression and proinflammatory mediators upon LPS stimulation, Journal of Leukocyte Biology, vol.79, issue.5, pp.989-98, 2006. ,
DOI : 10.1189/jlb.1005597
Chemokine response induced by Chlamydia trachomatis in prostate derived CD45+ and CD45- cells, Reproduction, vol.142, issue.3, pp.427-464, 2011. ,
DOI : 10.1530/REP-11-0163
The etiology and management of acute prostatitis, Nature Reviews Urology, vol.147, issue.4, pp.207-219, 2011. ,
DOI : 10.1038/nrurol.2011.22
Approach to urinary tract infections, Indian Journal of Nephrology, vol.19, issue.4, pp.129-168, 2009. ,
DOI : 10.4103/0971-4065.59333
Toll-like receptors and cancer, Nature Reviews Cancer, vol.5, issue.1, pp.57-63, 2009. ,
DOI : 10.1182/blood-2007-05-088682
Analysis of the inflammatory network in benign prostate hyperplasia and prostate cancer, The Prostate, vol.164, issue.2, pp.121-130, 2004. ,
DOI : 10.1002/pros.10317
Sequence Variants of Toll-Like Receptor 4 Are Associated with Prostate Cancer Risk: Results from the CAncer Prostate in Sweden Study, Cancer Research, vol.64, issue.8, pp.2918-2940, 2004. ,
DOI : 10.1158/0008-5472.CAN-03-3280
Study of TLR3, TLR4, and TLR9 in prostate carcinomas and their association with biochemical recurrence, Cancer Immunology, Immunotherapy, vol.164, issue.18, pp.217-243, 2011. ,
DOI : 10.1007/s00262-010-0931-0
Factor interaction analysis for chromosome 8 and DNA methylation alterations highlights innate immune response suppression and cytoskeletal changes in prostate cancer, Molecular Cancer, vol.6, issue.1, p.14, 2007. ,
DOI : 10.1186/1476-4598-6-14
Expression of toll-like receptor-9 is increased in poorly differentiated prostate tumors, The Prostate, vol.70, issue.9-10, pp.817-841, 2010. ,
DOI : 10.1002/pros.21115
Polymorphisms in Toll-like receptor genes and risk of cancer, Oncogene, vol.97, issue.2, pp.244-52, 2008. ,
DOI : 10.1158/1055-9965.EPI-05-0874
Are Toll-like receptor gene polymorphisms associated with prostate cancer?, Cancer Manag Res, vol.4, pp.23-32, 2012. ,
Association of Toll-like receptor (TLR) 2, 3 and 9 genes polymorphism with prostate cancer risk in North Indian population, Molecular Biology Reports, vol.16, issue.7, pp.7263-7272, 2012. ,
DOI : 10.1007/s11033-012-1556-5
Cancers take their Toll???the function and regulation of Toll-like receptors in cancer cells, Oncogene, vol.17, issue.2, pp.225-258, 2008. ,
DOI : 10.1126/science.1094351
Prostate cell lines secrete IL-8 in response tomycoplasma hominis through Toll-like receptor 2-mediated mechanism, The Prostate, vol.60, issue.4, pp.386-91, 2006. ,
DOI : 10.1002/pros.20358
Activation of Toll-like Receptor 4 on Tumor Cells In vitro Inhibits Subsequent Tumor Growth In vivo, Cancer Research, vol.67, issue.21, pp.10519-10546, 2007. ,
DOI : 10.1158/0008-5472.CAN-07-0079
Small interfering RNA-directed targeting of Toll-like receptor 4 inhibits human prostate cancer cell invasion, survival, and tumorigenicity, Molecular Immunology, vol.46, issue.15 ,
DOI : 10.1016/j.molimm.2009.06.016
Peroxiredoxin 1 Controls Prostate Cancer Growth through Toll-Like Receptor 4-Dependent Regulation of Tumor Vasculature, Cancer Research, vol.71, issue.5, pp.1637-1683, 2012. ,
DOI : 10.1158/0008-5472.CAN-10-3674
Toll like receptor-9 agonists stimulate prostate cancer invasion in vitro, The Prostate, vol.52, issue.7, pp.774-81, 2007. ,
DOI : 10.1002/pros.20562
The toll-like receptor pathway: A novel mechanism of infection-induced carcinogenesis of prostate epithelial cells, The Prostate, vol.26, issue.2, pp.223-232, 2008. ,
DOI : 10.1002/pros.20710
Trial Watch, OncoImmunology, vol.101, issue.5, pp.699-716, 2012. ,
DOI : 10.1038/nm0703-831
Targeting Toll-like receptors: emerging therapeutics?, Nature Reviews Drug Discovery, vol.11, issue.4, pp.293-307, 2010. ,
DOI : 10.1038/nrd3203
THE TREATMENT OF MALIGNAT TUMORS BY REPEATED INOCULATIONS OF ERYSIPELAS, The American Journal of the Medical Sciences, vol.105, issue.5, pp.487-510, 1893. ,
DOI : 10.1097/00000441-189305000-00001
Immunotherapeutic efficacy of Mycobacterium indicus pranii in eliciting anti-tumor T cell responses: Critical roles of IFN??, International Journal of Cancer, vol.54, issue.4 ,
DOI : 10.1002/ijc.26099
Antitumour effect of OM-174 and Cyclophosphamide on murine B16 melanoma in different experimental conditions, International Immunopharmacology, vol.5, issue.7-8, pp.1205-1217, 2005. ,
DOI : 10.1016/j.intimp.2005.02.013
ADJUVANT TREATMENT WITH POLYADENYLIC-POLYURIDYLIC ACID (POLYA.POLYU) IN OPERABLE BREAST CANCER, The Lancet, vol.316, issue.8187, pp.161-165, 1980. ,
DOI : 10.1016/S0140-6736(80)90057-4
Polyadenylic-polyuridylic acid as an adjuvant in resectable colorectal carcinoma: a 6 1/2 year follow-up analysis of a multicentric double blind randomized trial, Eur J Surg Oncol, vol.18, pp.599-604, 1992. ,
TLR3 as a Biomarker for the Therapeutic Efficacy of Double-stranded RNA in Breast Cancer, Cancer Research, vol.71, issue.5, pp.1607-1621, 2011. ,
DOI : 10.1158/0008-5472.CAN-10-3490
URL : https://hal.archives-ouvertes.fr/hal-00608171
Antitumor Activity of the TLR-5 Ligand Flagellin in Mouse Models of Cancer, The Journal of Immunology, vol.176, issue.11, pp.6624-6654, 2006. ,
DOI : 10.4049/jimmunol.176.11.6624
An Agonist of Toll-Like Receptor 5 Has Radioprotective Activity in Mouse and Primate Models, Science, vol.320, issue.5873, pp.226-256, 2008. ,
DOI : 10.1126/science.1154986
TLR7 and TLR8 as targets in cancer therapy, Oncogene, vol.14, issue.2, pp.190-199, 2008. ,
DOI : 10.1016/j.vaccine.2003.10.051
Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies, Journal of the American Academy of Dermatology, vol.50, issue.5, pp.722-755, 2004. ,
DOI : 10.1016/j.jaad.2003.11.066
Topical TLR7 Agonist Imiquimod Can Induce Immune-Mediated Rejection of Skin Metastases in Patients with Breast Cancer, Clinical Cancer Research, vol.18, issue.24, pp.6748-57, 2012. ,
DOI : 10.1158/1078-0432.CCR-12-1149
An Exploratory Study of Systemic Administration of the Toll-like Receptor-7 Agonist 852A in Patients with Refractory Metastatic Melanoma, Clinical Cancer Research, vol.14, issue.3, pp.856-64, 2008. ,
DOI : 10.1158/1078-0432.CCR-07-1938
Toll-like receptor 9 (TLR9) agonists in the treatment of cancer, Oncogene, vol.89, issue.2, pp.161-168, 2008. ,
DOI : 10.1182/blood-2004-03-1190
Randomized Phase II Trial of a Toll-Like Receptor 9 Agonist Oligodeoxynucleotide, PF-3512676, in Combination With First-Line Taxane Plus Platinum Chemotherapy for Advanced-Stage Non???Small-Cell Lung Cancer, Journal of Clinical Oncology, vol.26, issue.24 ,
DOI : 10.1200/JCO.2007.12.5807
Randomized Phase III Trial of Paclitaxel/Carboplatin With or Without PF-3512676 (Toll-Like Receptor 9 Agonist) As First-Line Treatment for Advanced Non???Small-Cell Lung Cancer, Journal of Clinical Oncology, vol.29, issue.19, pp.2667-74, 2011. ,
DOI : 10.1200/JCO.2010.32.8971
In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study, Journal of Clinical Oncology, vol.28, issue.28, pp.4324-4356, 2010. ,
DOI : 10.1200/JCO.2010.28.9793
Phase II Trial of a Toll-Like Receptor 9???Activating Oligonucleotide in Patients With Metastatic Melanoma, Journal of Clinical Oncology, vol.24, issue.36, pp.5716-5740, 2006. ,
DOI : 10.1200/JCO.2006.07.9129
Molecular genetics of prostate cancer: new prospects for old challenges, Genes & Development, vol.24, issue.18, pp.1967-2000, 2010. ,
DOI : 10.1101/gad.1965810
Ampligen: A potential toll-like 3 receptor adjuvant for immunotherapy of cancer, Vaccine, vol.27, issue.25-26, pp.3401-3405, 2009. ,
DOI : 10.1016/j.vaccine.2009.01.071
Toll-like receptor 3 triggers apoptosis of human prostate cancer cells through a PKC-??-dependent mechanism, Carcinogenesis, vol.29, issue.7, pp.1334-1376, 2008. ,
DOI : 10.1093/carcin/bgn149
Toll-like receptor 3 regulates angiogenesis and ,